Obesity drug is licensed in the UKBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7162.835 (Published 26 September 1998) Cite this as: BMJ 1998;317:835
- Alex Brooks
Fears of a £750m ($1.2bn) annual drugs bill for orlistat (Xenical), a drug for obesity launched this week in Britain, have led to inevitable comparisons with sildenafil (Viagra). Unlike sildenafil, however, the drug has been put on the NHS drugs list after approval by the European Medicines Evaluation Agency.
The manufacturer, Roche Pharmaceuticals, announced this week that a single tablet will cost 51p. The predicted cost of £750m, widely reported in the media, assumed a cost of over £1 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial